Selective O-GlcNAcase Inhibitors for Tauopathies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current inhibitors for O-GlcNAcase are non-selective, affecting multiple functionally related enzymes, leading to complex phenotypes and limited efficacy in treating diseases associated with tau hyperphosphorylation, such as Alzheimer's and related tauopathies.
Innovation Solution
Development of specific compounds represented by structural formulas that selectively inhibit O-GlcNAcase, potentially reducing tau hyperphosphorylation and addressing age-related glucose metabolism impairments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective inhibitors are used to block O-GlcNAcase function, then inhibition of the target enzyme is achieved, but lysosomal beta-hexosaminidases are also inhibited leading to complex phenotypes
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features (such as the heterocyclic core structure and specific substituent patterns) that confer selectivity for O-GlcNAcase over other beta-hexosaminidases. This is achieved through tailored chemical modifications at specific positions of the inhibitor molecule, creating localized interactions that distinguish the target enzyme from related enzymes.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters of the inhibitor structure (substituents R1-R6, heterocyclic variations) to optimize selectivity. By adjusting these chemical parameters, the inhibitors achieve differential binding affinity for O-GlcNAcase versus lysosomal beta-hexosaminidases, resolving the selectivity issue.
2Reliability
If existing beta-N-acetylglucosaminidase inhibitors are used, then O-GlcNAcase function is blocked, but lysosomal beta-hexosaminidases are also affected reducing treatment efficacy
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor design into distinct functional modules: a core heterocyclic structure and specific substituent groups (R1-R6). This modular approach allows independent optimization of each segment for selectivity and potency, enabling the inhibitor to specifically target O-GlcNAcase while preserving lysosomal beta-hexosaminidase activity.
Solution Approach 2:
The patent uses the specially designed chemical structure as an intermediary that selectively interacts with O-GlcNAcase. The heterocyclic core with specific substituents acts as a mediator that recognizes and binds to the unique active site features of O-GlcNAcase, preventing off-target inhibition of lysosomal enzymes and thereby improving therapeutic efficacy.
Data Source
AI summary
Described herein are compounds represented by formula (I") or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, Ra, Rb, m, n, Y1, Y2, R3 and R4 are defined herein.